PDF factsheet
      Z

Anthracyclines based regimen in advanced breast cancer (metastatic) for all type of patients, clinical trials results

CAF versus CMFVP
Smalley, 1983
cyclophosphamide, doxorubicin, and 5-fluorouracil (CAF)
versus
cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prednisone (CMFVP)
CNF versus CAF
Stewart, 1997
CNF intravenous cyclophosphamide 500 mg/m2 plus fluorouracil 500 mg/m2 + mitoxantrone 10 mg/m2 every 3 weeks
versus
CAF intravenous cyclophosphamide 500 mg/m2 plus fluorouracil 500 mg/m2 + doxorubicin (Adriamycin) 50 mg/m2 every 3 weeks
advanced breast canceropen
FAC versus FEC
French Epirubicin Study , 1988
fluorouracil, 500 mg/m2; cyclophosphamide, 500 mg/m2; and either epirubicin
versus
doxorubicin
Italian Study, 1988
fluorouracil, epirubicin, and cyclophosphamide
versus
fluorouracil, doxorubicin, and cyclophosphamide
FEC x 24 + tamoxifen versus FEC x 8 + tamoxifen
Ejlertsen,
cyclophosphamide, epirubicin and 5-fluorouracil (CEF) once every 3 weeks for a maximum of 18 months
versus
identical chemotherapy for a maximum of 6 months
MV versus FAC/FEC
Namer, 2001
mitoxantrone+vinorelbine (MV)
versus
5-fluorouracil+cyclophosphamide+either doxorubicin or epirubicin (FAC/FEC)
sequentially versus combination
ANZBC, 1986
treatment sequences, doxorubicin plus cyclophosphamide (AC) followed on failure by tamoxifen (TAM), and TAM followed by AC
versus
combined modality chemo-endocrine therapy (TAM plus AC).

  Options


in first

in second

  Filter